{"id":"patidegib-topical-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions (erythema, irritation)"},{"rate":null,"effect":"Dermatitis"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2105764","moleculeType":"Small molecule","molecularWeight":"541.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Patidegib inhibits smoothened, a key component of the hedgehog signaling pathway that is aberrantly activated in basal cell carcinoma and other skin cancers. By blocking this pathway, the drug suppresses tumor cell growth and proliferation. As a topical gel formulation, it delivers the active agent directly to affected skin lesions while minimizing systemic exposure.","oneSentence":"Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:43.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Basal cell carcinoma (topical treatment)"},{"name":"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"}]},"trialDetails":[{"nctId":"NCT06050122","phase":"PHASE3","title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2024-03-17","conditions":"Gorlin Syndrome","enrollment":140},{"nctId":"NCT04308395","phase":"PHASE3","title":"Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)","status":"TERMINATED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2020-06-03","conditions":"Basal Cell Nevus Syndrome","enrollment":108},{"nctId":"NCT03703310","phase":"PHASE3","title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2019-02-19","conditions":"Basal Cell Nevus Syndrome","enrollment":174},{"nctId":"NCT04155190","phase":"PHASE2","title":"An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC","status":"TERMINATED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2019-12-20","conditions":"Recurrent Basal Cell Carcinoma","enrollment":47},{"nctId":"NCT02762084","phase":"PHASE2","title":"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","status":"COMPLETED","sponsor":"PellePharm, Inc.","startDate":"2016-06-06","conditions":"Basal Cell Nevus Syndrome","enrollment":17},{"nctId":"NCT02828111","phase":"PHASE2","title":"Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas","status":"COMPLETED","sponsor":"PellePharm, Inc.","startDate":"2016-11-11","conditions":"Basal Cell Carcinomas","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Patidegib","IPI-926","Saridegib","SGT-610"],"phase":"phase_3","status":"active","brandName":"Patidegib Topical Gel","genericName":"Patidegib Topical Gel","companyName":"Sol-Gel Technologies, Ltd.","companyId":"sol-gel-technologies-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors. Used for Basal cell carcinoma (topical treatment), Nevoid basal cell carcinoma syndrome (Gorlin syndrome).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}